Clinical Trials Logo

Myelofibroses clinical trials

View clinical trials related to Myelofibroses.

Filter by:
  • None
  • Page 1

NCT ID: NCT03718143 Terminated - Clinical trials for Acute Myeloid Leukemia

AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis

Start date: May 8, 2019
Phase: Phase 2
Study type: Interventional

A phase II study testing the efficacy of combined AZD1775 with AraC or single agent activity of AZD1775 in three arms: Arm A has subjects age 60 years or older who are newly diagnosed with AML receiving the combination of the drugs; Arm B has subjects who are have relapsed/refractory AML and HMA failure MDS patients being allocated to either the combination Arm B or single agent AZD1775 Arm C.

NCT ID: NCT03386214 Terminated - Myelofibroses Clinical Trials

Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis

Start date: April 23, 2018
Phase: Phase 1
Study type: Interventional

Based on the investigators' preclinical data, the combination of pevonedistat and ruxolitinib may provide greater clinical responses in patients with myelofibrosis compared to ruxolitinib monotherapy via inhibition of NFκB in addition to JAK-STAT signaling.

NCT ID: NCT03326310 Recruiting - Clinical trials for Chronic Myeloid Leukemia

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

Start date: September 4, 2018
Phase: Phase 1
Study type: Interventional

This is a phase I, open-label, dose-escalation study to determine the MTD of selumetinib when combined with the standard dose of azacitidine. Treatment will begin within 28 days of screening procedures. Treatment will continue indefinitely, provided that the patient continues to derive benefit. A patient will be taken off study for reasons described in detail in section 3.12 including disease progression, unacceptable toxicity, inter-current illness, withdrawal of consent, or at the discretion of the investigator. Patients will be followed for 12 weeks after the last dose of study drug, until any study treatment related toxicities have stabilized, or until death. The total duration of the study is expected to be approximately 24 months.